Complete HealthCare Solutions, Inc. (CHS) Receives the eMDs, a Marlin Equity Portfolio Company, Annual Lytec / LytecMD Business Partner Award
PALMER, Mass., July 17, 2018 /PRNewswire/ -- Complete HealthCare Solutions, Inc. has been named Lytec and LytecMD Value Added Reseller of the Year by eMDs a Marlin Equity Portfolio company.
The Value-Added Reseller Award honors best-in-class, including sales, service, support and innovation with-in the eMDs Lytec and LytecMD ambulatory solutions portfolio. This honor is awarded to only one of over 100 eMDs business partners each year.
Primarily serving the ambulatory market, Lytec and LytecMD require the personalized service and support only CHS can provide, ensuring a successful implementation. CHS's added expertise in industry requirements, reporting, medical billing, patient engagement and cloud hosting is a huge differentiating factor in the awarding of this honor.
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...
